Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10% ...

Boston Scientific (NYSE:BSX) recently entered into a significant agreement with Bittium Biosignals Ltd. to supply ECG devices, valued between USD 30 to 45 million, which strengthens their cardiac ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will no longer pursue an approval in the U.S., following recent stu | It’s ...

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Boston Scientific agreed to pay Johnson & Johnson $600 million in connection with Johnson & Johnson’s botched acquisition of Guidant, a medical device company, in 2004.

Shares of Boston Scientific slipped 0.7% to $105.46 in early trading Wednesday, while shares of Edwards rose 1.8% to $77.60 and shares of Medtronic gained 1.1% to $82.06.

Boston Scientific on Wednesday said it is ending worldwide sales of its Acurate neo2 and Prime aortic valve systems, and that it is no longer pursuing regulatory approvals for Acurate in the U.S ...

Boston Scientific (NYSE:BSX) shares fell 4% after the company announced it will discontinue global sales of its ACURATE neo2 and ACURATE Prime Aortic Valve Systems. The decision follows ...

Boston Scientific (BSX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Call Start: 08:01 January 1, 0000 8:50 AM ETBoston Scientific Corporation (NYSE:BSX)Bernstein 41st Annual Strategic Decisions Conference CallMay 28, 2025 ...

In the latest market close, Boston Scientific (BSX) reached $104.50, with a -0.01% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.4%.